Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Trial

Official title:

Efficacy and Safety of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05322733
• Other study ID #: CWCLL-001
• Status: Recruiting
• Phase: Phase 2
• Start date: April 15, 2022
• Est. completion date: November 5, 2025

Study information

• Verified date: April 2022
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Jianyong Li, Phd, MD
• Phone: 025-83718836
• Email: lijianyonglm[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Description:

Patients eligible for enrollment will receive 7-day lead-in therapy of orelabrutinib 150 mg once daily, followed by 3 cycles of orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (oFCG) at 28-day intervals. After 3 cycles, bone marrow (BM) minimal residual disease (MRD) detection and efficacy evaluation (iwCLL2018 guidelines) are conducted. If BM MRD is negative (<10-4), patients will receive be treated with orelabrutinib plus obinutuzumab in 4-6 cycles; If BM MRD is positive (≥10-4), patients will receive the same regimen in 4-6 cycles as in previous 3 cycles. After 6 cycles of treatment, BM MRD detection and efficacy assessment will be conducted again. If BM MRD is negative (<10-4), orelabrutinib monotherapy will be administered in 7-12 cycles; If BM MRD is positive (≥10-4), treatment with orelabrutinib plus obinutuzumab will be administered in 7-12 cycles. After 12 cycles of treatment, BM MRD detection and efficacy evaluation will be performed. If BM MRD is negative (<10-4), orelabrutinib will be withdrawn and participants will turn to follow-up (efficacy assessment and MRD test will be performed according to the follow-up plan); if BM MRD is positive, treatment with orelabrutinib monotherapy will be administered in 13-24 cycles (continued even if BM MRD test was negative). After 24 cycles, if BM MRD is negative, the drug can be stopped and participants turn to follow-up. If BM MRD is positive, treatment can be continued until disease progression or be ceased by investigator due to no benefit from continued treatment, and BM MRD can be tested as planned. The trial is expected to end 36 months after enrollment of the last patient. If the subjects continue to require subsequent treatment with orelabrutinib, the sponsor will coordinate with the manufacturer and continue to provide the monotherapy treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: November 5, 2025
• Est. primary completion date: February 22, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age between 18 to 65 years old for both gender.

2. Patients have a confirmed diagnosis of CD20-positive chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and meet criteria to initiate first-line treatment per International Workshop on CLL Working Group (IWCLL) 2018 guidelines

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

4. At least one measurable disease detected by enhanced computerized tomography (CT) or magnetic resonance imaging (MRI). At least one lymph node with the longest axis >=1.5cm and one measurable vertical dimension.

5. With life expectancy > 6 months.

6. Patients must meet the following laboratory examination criteria during 14 days before entry:

Serum bilirubin <1.5 Upper Limit of Normal (ULN), other than gilbert syndrome (defined as unconjugated bilirubin>80%); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 ULN.

Absolute neutrophil count (ANC)=0.75×109/L and Platelets=50×109/L (patients without exposure to G-CSF or blood transfusion within 7 days and no exposure to )

Exclusion Criteria:

1. Cumulative illness rating scale (CIRS) > 6.

2. Creatinine clearance rate (Ccr) <70 ml/min calculated by Cockcroft-Gault formula or by 24-hour urine analysis.

3. Patients diagnosed as other malignancy except lymphoma, except patients with curative intent and with no known active disease present for = 5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.

4. Patients with known central nervous system involvement.

5. Patients with progressive multifocal leukoencephalopathy (PML).

6. Patients with history of Richter's Syndrome or suspected Richter's Syndrome.

7. Uncontrolled autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura, e.g. persistent decreasing hemoglobin or platelet count requiring steroid therapy 4 weeks before initiation of study.

8. Prior exposure to systemic therapy for CLL/SLL (except for incomplete treatment regimens fewer than 2 weeks such as antitumor steroid therapy).

9. Prior exposure to live vaccines, immunotherapy or other investigational therapeutic agent within 4 weeks prior to enrollment.

10. Requiring persistent steroid therapy for other non-antitumor purposes. Systemic steroid drug use within 7 days of first dose of study drug except regional use of steroid drug.

11. Uncontrolled or other serious cardiovascular disease, including:

1. New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, or clinically significant arrhythmia requiring medical intervention with a left ventricular ejection fraction (LVEF) <50% at screening 6 months prior to initial administration of the study drug;

2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, rhythmogenesis right ventricular cardiomyopathy, restricted cardiomyopathy, unshaped cardiomyopathy);

3. Clinically significant prolonged QTc interval, or QTc interval >470 ms in female and >450 ms in male at screening;

4. Uncontrolled hypertension: on the basis of lifestyle improvement, blood pressure still fails to reach the standard after application of 2 or more kinds of reasonable, tolerable and full dose antihypertensive drugs (including diuretics), or 4 or more kinds of antihypertensive drugs until blood pressure can be effectively controlled.

12. Active bleeding within 2 months prior to screening, or taking anticoagulant/platelet drugs, or have a definite bleeding tendency in the investigator's opinion (e.g., esophageal varices with bleeding risk, local active ulcer lesions);

13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

14. Clinically significant gastrointestinal abnormalities that may affect drug ingestion, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy.

15. Major surgery within 4 weeks of first dose of study drug. Diagnostic examination is not regarded as surgery and insertion of vascular access device excluded from the criteria.

16. Uncontrolled active systemic fungi, bacteria, virus (e.g. CMV DNA positive by PCR analysis) or other infections (defined as showing persistent symptoms of infection and no improvement although appropriate antibiotics or other treatment have been applied), or requiring intravenous (IV) antibiotics administration.

17. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection (positive results from PCR analysis).

18. Known hypersensitivity to Orelabrutinib, Fludarabine, Cyclophosphamide or Obinutuzumab

19. Concurrent treatment with strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers.

20. Any mental or cognitive impairment that may limit their understanding of informed consent and compliance with the study.

21. Pregnant and lactating women, or women of childbearing age who are unwilling to use contraception throughout the study period and within 18 months of the last administration of obinutuzumab or within 180 days of the last administration of any other study drug (women who were fertile must have a negative serological pregnancy test within 14 days prior to initiation of study) Male without surgically sterilized who are unwilling to use contraception throughout the study period and within 180 days of the last administration of the study drug.

22. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma

Intervention

Drug:
• Orelabrutinib
150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
• Obinutuzumab
1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
• Fludarabine
25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
• Cyclophosphamide
250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).

Locations

Country	Name	City	State
China	Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital	Nanjin	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PB and BM Undetectable MRD rate by Next-generation Sequencing (NGS ) after 3, 6, 12 and 24 cycles.	Participants who achieve BM and PB uMRD (<10-6) detected by NGS after 3 and 6 cycles. Participants who achieve BM uMRD (<10-6) detected by NGS after 12 and 24 cycles.	at the end of 3, 6, 12 and 24 cycles(each cycle is 28 days)
Primary	BM undetectable MRD rate after 6 cycles	Participants who achieve bone marrow (BM) undetectable Minimal Residue Disease (uMRD) after 6 cycles detecting by four-color flow cytometry with a detection level of 10-4.	at the end of 6 cycles(each cycle is 28 days)
Secondary	BM and PB undetectable MRD ratev after 3, 12, 24 cycles.	participants who achieve BM uMRD (<10-4) on other important evaluation time-point (e.g. after 3, 12 and 24 cycles) except after 6 cycles. participants who achieve peripheral blood (PB) uMRD (<10-4) on important evaluation time-point.	at the end of 3, 12, 24 cycles(each cycle is 28 days)
Secondary	Objective Response Rate (ORR)	Response assessed after 3 and 6 cycles and up to approximately 3 years.	at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
Secondary	Complete Remission Rate (CRR)	Response assessed after 3 and 6 cycles and up to approximately 3 years.	at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
Secondary	Duration of Response (DOR)	DOR is defined as duration in days from the data of initial documentation of objective response to the date of first documented evidence of progressive disease (PD) or death from any cause. Response and PD are defined according to iwCLL 2018 guidelines.	up to approximately 2, 3 years
Secondary	Progression Free Survival (PFS)	PFS is defined as duration from the date of enrollment to date of progressive disease, replase, or death from any cause, whichever occurs first. PD are defined according to iwCLL 2018 guidelines.	up to 3 years
Secondary	Overall Survival (OS)	OS is defined as the time from the date of enrollment to the date of the participant's death from any cause.	up to 3 years
Secondary	Incidence of adverse events (AEs)	Treatment emergent adverse events (TEAE), severe adverse events (SAEs), adverse events of special interest (AESIs) and therapy-related AEs will be recorded and graded will be summarized by grade according to CTCAE (version 5.0).	through study completion, an average of 4 year"